PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals (NASDAQ:ANAC) reported today its second quarter accomplishments and financial results for the three months ended June 30, 2011. “We continued to make progress on our lead programs in the second quarter. We are enrolling patients in our two Phase 3 trials of AN2690 for onychomycosis, we completed our final Phase 2b trial of AN2728 for psoriasis and are preparing for our End of Phase 2 meeting with the FDA, and we announced that our partner GSK initiated two Phase 2b trials of GSK ‘052,” said David Perry, Chief Executive Officer of Anacor Pharmaceuticals. “We have also made progress in our neglected diseases initiative with our partner DNDi announcing the completion of pre-clinical studies of AN5568 for African Sleeping Sickness and their plans to move the compound into clinical development. More recently, we announced that Eli Lilly, our partner in animal health, has selected an Anacor compound to develop for a significant unmet need in animal health.”
